Year: 2025
Type: article
Abstract: Clevidipine is a third generation dihydropyridine and is a multiple Ca2+ channel blocker approved for clinical use and clevidipine is used for intravenous management of hypertension. Clevidipine has been found efficacy and safe in hypertensive patients but induces some adverse-effects which occur in a limited rate. Six studies have been reported on treatment of hypertensive patients with clevidipine and three studies have been reported on clinical trials conducted with clevidipine in hypertensive patients. Clevidipine is metabolized into the inactive metabolite H152/81.
Author: Gian Maria Pacifici
Language: English
Subfield: Cardiology and Cardiovascular Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
Funder: Università di Pisa
OpenAlex ID: W4409411543